Polyrizon (PLRZ) News Today $1.08 +0.04 (+3.85%) As of 03:37 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Polyrizon Regains Nasdaq ComplianceAugust 14, 2025 | msn.comPolyrizon Ltd. Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | quiverquant.comQPolyrizon Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | globenewswire.comPolyrizon Ltd. Announces Special General Meeting for September 2025July 31, 2025 | tipranks.comPolyrizon stock soars after promising nasal allergy blocker test resultsJuly 23, 2025 | in.investing.comPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudyJuly 22, 2025 | globenewswire.comPolyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | finanznachrichten.dePolyrizon retains Nasdaq listing following hearings panelJuly 15, 2025 | msn.comPolyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | globenewswire.comPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comQPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comPolyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant ExercisesMay 14, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | finanznachrichten.dePolyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | globenewswire.comPolyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail InterestMay 5, 2025 | msn.comPolyrizon reports safety study results for PL-14 Allergy Blocker formulationApril 26, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | finanznachrichten.dePolyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | globenewswire.comPolyrizon Ltd. Shareholders Approve Key Amendments at Annual MeetingApril 17, 2025 | tipranks.comPolyrizon Faces Nasdaq Compliance ChallengeApril 11, 2025 | tipranks.comPolyrizon Receives Nasdaq Notification Regarding Minimum Bid RequirementsApril 11, 2025 | globenewswire.comPolyrizon entered into agreement with branding, trademark consultancy firmApril 3, 2025 | markets.businessinsider.comPolyrizon Partners with Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | tipranks.comPolyrizon Engages Leading Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | globenewswire.comPolyrizon Ltd. Secures $17 Million in Private Placement to Advance Hydrogel TechnologyApril 1, 2025 | tipranks.comPolyrizon Ltd. Announces Closing of $17.0 Million Private PlacementApril 1, 2025 | globenewswire.comPolyrizon announces $17M private placementMarch 31, 2025 | markets.businessinsider.comPolyrizon Ltd. Announces $17.0 Million Private PlacementMarch 31, 2025 | globenewswire.comPolyrizon Advances Clinical Strategy For PL-14 Allergy Blocker Ahead Of FDA MeetingMarch 29, 2025 | nasdaq.comPolyrizon structures clinical strategy for allergy blocker PL-14March 28, 2025 | markets.businessinsider.comPolyrizon Prepares Clinical Strategy for Allergy Blocker PL-14March 27, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue TreatmentMarch 27, 2025 | finanznachrichten.dePolyrizon begins preclinical studies for seizure treatmentMarch 27, 2025 | uk.investing.comPolyrizon begins BZDs studies for treating ARS and status epilepticusMarch 27, 2025 | markets.businessinsider.comPolyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission MeetingMarch 27, 2025 | globenewswire.comPolyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue TreatmentMarch 25, 2025 | globenewswire.comClearmind Medicine To Develop Novel Intranasal Formulation With PolyrizonMarch 21, 2025 | nasdaq.comClearmind signs non-binding LOI with Polyrizon for intranasal drug deliveryMarch 19, 2025 | markets.businessinsider.comPolyrizon Expands Intranasal Platform for Psychedelic TreatmentsMarch 14, 2025 | tipranks.comPolyrizon signs non-binding LOI to expand its intranasal drug delivery platformMarch 14, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge PlatformMarch 14, 2025 | finanznachrichten.dePolyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based TreatmentsMarch 14, 2025 | globenewswire.comPolyrizon launches preclinical studies for intranasal naloxoneMarch 13, 2025 | markets.businessinsider.comPolyrizon Ltd. Schedules Annual General Meeting for April 2025March 13, 2025 | tipranks.comPolyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge PlatformMarch 13, 2025 | globenewswire.comPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024March 11, 2025 | globenewswire.com Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRZ Media Mentions By Week PLRZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRZ News Sentiment▼1.871.03▲Average Medical News Sentiment PLRZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRZ Articles This Week▼11▲PLRZ Articles Average Week Get the Latest News and Ratings for PLRZ and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Polyrizon and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Enlivex Therapeutics News Cadrenal Therapeutics News Reviva Pharmaceuticals News Rallybio News FibroBiologics News Natural Alternatives International News Passage Bio News Tharimmune News Q32 Bio News NanoViricides News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRZ) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access